These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35699794)

  • 1. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade.
    Kirtonia A; Pandey AK; Ramachandran B; Mishra DP; Dawson DW; Sethi G; Ganesan TS; Koeffler HP; Garg M
    Cell Mol Life Sci; 2022 Jun; 79(7):362. PubMed ID: 35699794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of LAMC2 Reverses Epithelial Mesenchymal Transition and Inhibits Progression in Pancreatic Ductal Adenocarcinoma via Inactivation of the NF-κB Signaling Pathway.
    Huang L; Han Y; Zhou Q; Sun Z; Yan J
    Crit Rev Eukaryot Gene Expr; 2023; 33(4):13-23. PubMed ID: 37183943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y; Takahashi N; Takayama T; Goel A
    Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
    Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laminin‑332 mediates proliferation, apoptosis, invasion, migration and epithelial‑to‑mesenchymal transition in pancreatic ductal adenocarcinoma.
    Huang C; Chen J
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth.
    Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
    Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
    Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
    Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT.
    Yuan Q; Zhang Y; Feng L; Jiang Y
    J Cell Biochem; 2019 Jan; 120(1):552-561. PubMed ID: 30203487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.
    Zhang H; Pan YZ; Cheung M; Cao M; Yu C; Chen L; Zhan L; He ZW; Sun CY
    Cell Death Dis; 2019 Mar; 10(3):230. PubMed ID: 30850586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.
    Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y
    Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma.
    Yang T; Shen P; Chen Q; Wu P; Yuan H; Ge W; Meng L; Huang X; Fu Y; Zhang Y; Hu W; Miao Y; Lu Z; Jiang K
    J Exp Clin Cancer Res; 2021 Aug; 40(1):261. PubMed ID: 34416910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.
    Garg M; Kanojia D; Okamoto R; Jain S; Madan V; Chien W; Sampath A; Ding LW; Xuan M; Said JW; Doan NB; Liu LZ; Yang H; Gery S; Braunstein GD; Koeffler HP
    J Clin Endocrinol Metab; 2014 Jan; 99(1):E62-72. PubMed ID: 24170107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway.
    Zhou S; Wang Z; Zhao D; Fu Y; Zhang S; Wang Z; Zou X
    World J Surg Oncol; 2024 May; 22(1):133. PubMed ID: 38762741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
    PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K.
    Gurbuz N; Kahraman N; Sonmez HE; Mokhlis HA; Kosar PA; Ozpolat B
    Anticancer Agents Med Chem; 2022; 22(14):2607-2618. PubMed ID: 35718922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer.
    Cave DD; Buonaiuto S; Sainz B; Fantuz M; Mangini M; Carrer A; Di Domenico A; Iavazzo TT; Andolfi G; Cortina C; Sevillano M; Heeschen C; Colonna V; Corona M; Cucciardi A; Di Guida M; Batlle E; De Luca A; Lonardo E
    J Exp Clin Cancer Res; 2022 Oct; 41(1):315. PubMed ID: 36289544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.